

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 10, 2011**

---

**OraSure Technologies, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-16537**  
(Commission  
File Number)

**36-4370966**  
(I.R.S. Employer  
Identification No.)

**220 East First Street**  
**Bethlehem, Pennsylvania**  
(Address of Principal Executive Offices)

**18015-1360**  
(Zip Code)

**Registrant's telephone number, including area code: 610-882-1820**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.**

On November 10, 2011, Gerald M. Ostrov was appointed as a new member of the Board of Directors (the "Board") of OraSure Technologies, Inc. (the "Company"). Mr. Ostrov is filling a vacancy on the Board and will serve as a Class I Director for a term expiring at the Company's Annual Meeting of Stockholders in 2013. Mr. Ostrov has not been appointed to a Committee of the Board.

Pursuant to the Company's Non-Employee Director Compensation Policy, Mr. Ostrov was granted an option to purchase 40,000 shares of the Company's Common Stock with an exercise price equal to the mean between the high and low sales prices of the Company's common stock on the date of his appointment. The foregoing option will vest on a monthly basis over the 24-month period following the grant date. Vesting will be accelerated in the event of a change in control involving the Company.

A press release, dated November 10, 2011, announcing Mr. Ostrov's appointment to the Board, is attached as Exhibit 99 to this Report and is incorporated by reference herein.

**Item 9.01 – Financial Statements and Exhibits.**

**(d) Exhibits**

<u>Exhibit Number</u>	<u>Description</u>
99	Press Release, dated November 10, 2011, announcing the appointment of Gerald M. Ostrov as a member of the Company's Board of Directors.

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: November 10, 2011

By: /s/ Jack E. Jerrett

Jack E. Jerrett

Senior Vice President, General Counsel and Secretary

---

**Index to Exhibits**

**Exhibit  
No.**

**Description**

99

Press Release, dated November 10, 2011, announcing the appointment of Gerald M. Ostrov as a member of the Company's Board of Directors.



Investor Contact:  
Ronald H. Spair  
Chief Financial Officer  
610-882-1820  
investorinfo@orasure.com

Media Contact:  
Jennifer Moritz  
Zero to Five for OraSure Technologies  
917-748-4006  
jmoritz@0to5.com

**OraSure Technologies Appoints Veteran Consumer Products Executive to its Board of Directors**

BETHLEHEM, Pa. – November 10, 2011 – OraSure Technologies, Inc. (NASDAQ:OSUR) today announced the appointment of Gerald M. Ostrov as a member of the Company’s Board of Directors. Mr. Ostrov will serve as a Class I Director with an initial term expiring in 2013.

“We are very pleased to welcome Gerald Ostrov, a highly successful and seasoned healthcare executive, to our Board of Directors,” said Douglas G. Watson, Chairman of the Board of OraSure Technologies. “Jerry has a long history of innovation and success in the healthcare industry and his extensive expertise in consumer packaged goods will be extremely valuable as we broaden our product offerings in the over-the-counter market. We look forward to Jerry’s contributions to the Company’s future success.”

Mr. Ostrov has a strong track record leading and innovating global businesses in consumer products, medical device and pharmaceutical industries. He most recently served as Chairman and CEO of Bausch & Lomb from 2008 through 2010, where he stabilized and restructured the business following its privatization by private equity investors. During his tenure, Mr. Ostrov focused on building a pipeline for the future while improving profitability and cash flow.

Prior to this position, Mr. Ostrov spent the majority of his career with Johnson & Johnson where he held the position of Company Group Chairman responsible for the Worldwide Vision Care businesses for nearly eight years, until his retirement in 2006. In that capacity, Mr. Ostrov and his team delivered a consistent flow of global product innovation which dramatically increased sales and grew profitability even faster.

Mr. Ostrov began his career with Johnson & Johnson’s Health Care Division in 1976. In 1982, he left Johnson & Johnson to become Vice President of Marketing for Ciba-Geigy’s Consumer Pharmaceuticals Company. He was named President of Ciba Consumer Pharmaceuticals in 1985 and served in that capacity until rejoining Johnson & Johnson in 1991 as President of the corporation’s Personal Products Company. In 1993, he was promoted to Company Group Chairman and added Northern Europe Consumer and Personal Care products to his responsibilities. In 1995, he became responsible for all Consumer and Personal Care businesses in North America. He assumed Vision Care global responsibilities in 1998.

---

Mr. Ostrov's current focus is on consulting and developing new technologies in the consumer products and consumer medical device fields.

Mr. Ostrov earned his Bachelor of Science degree with distinction in Industrial Engineering and Operations Research from Cornell University and holds an M.B.A. from Harvard University.

### **About OraSure Technologies**

OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, through its wholly-owned subsidiary, DNA Genotek Inc., the Company also is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit [www.orasure.com](http://www.orasure.com).